|
Drug Use Review of Bisphosphonates and Raloxifene for Osteoporosis Treatment at the Postmenopausal Clinic, Health Promoting Hospital, Regional Health Promotion Center 6 |
|---|---|
| รหัสดีโอไอ | |
| Creator | Prachit Kangsaun |
| Title | Drug Use Review of Bisphosphonates and Raloxifene for Osteoporosis Treatment at the Postmenopausal Clinic, Health Promoting Hospital, Regional Health Promotion Center 6 |
| Contributor | Ornanong Waleekhajornlert, Chulaporn Limwattananon, Sumon Sakolchai |
| Publisher | Faculty of Pharmaceutical Sciences KKU MSU UBU |
| Publication Year | 2551 |
| Journal Title | Isan Journal ofPharmaceutical Sciences |
| Journal Vol. | 4 |
| Journal No. | 2 |
| Page no. | 46-56 |
| Keyword | review, bisphosphonates, raloxifene, osteoporosis, postmenopause |
| URL Website | https://tci-thaijo.org/index.php/IJPS |
| Website title | Isan Journal ofPharmaceutical Sciences, IJPS |
| ISSN | 19050852 |
| Abstract | This study aimed to review prescribing of bisphosphonates and raloxifene for osteoporosis treatment at the postmenopausal clinic, Health Promoting Hospital, Regional Health Promotion Center 6, Khon Kaen. A review of chart and registry was performed. All medical charts between January 2003 and June 2008 were reviewed (N=103). In this study, indication, dosage, and duration of treatment were examined. Findings showed that all prescribing of alendronate and risedronate were appropriate with recommended indications. The rate of appropriate use of raloxifene was 65% (13 from 20 patients who received raloxifene as the first choice medication). Medications were prescribed as continuous basis. Medications were changed or discontinued only when adverse events occurred or bone mineral density (BMD) T-score decreased from baseline. BMD monitoring for two years after Starting drug treatment was conducted in a small proportion of patients. Three of patients had adverse events in gastrointestinal system including glossitis and abdominal pain from alendronate and risedronate. |
